We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Biomarker Predicts Likelihood of HIV Patients to Develop Fungal Meningitis

By LabMedica International staff writers
Posted on 11 Sep 2013
A specific genotype has been identified as a potential biomarker for the likelihood of HIV patients to develop fungal meningitis (cryptococcal disease or CD) from infection by Cryptococcus neoformans.

Cryptococcus neoformans is one of the most common causes of fungal disease in HIV-infected persons due to their low levels of CD4+ T-cells, but not all of those who are infected with C. More...
neoformans develop meningitis.

Although CD4+ T-cell deficiency is a risk factor for HIV-associated CD, polymorphisms of phagocytic Fc gamma receptors (FCGRs) have been linked to CD risk in HIV-uninfected persons. To investigate associations between FCGR2A 131 H/R and FCGR3A 158 F/V polymorphisms and CD risk in HIV-infected persons, investigators at the Albert Einstein College of Medicine (New York, NY, USA) performed PCR-based genotyping on banked samples from 164 men enrolled in the Multicenter AIDS Cohort Study. These samples included 55 from patients infected with HIV who developed CD and matched control groups of 54 patients who were HIV-infected and 55 men who were HIV-uninfected.

Results of the study revealed that after correcting for demographic factors and T-cell counts, a strong association was found between the gene for the high-affinity FCGR3A 158V allele and the risk of CD in the HIV-infected men.

In binding studies, human IgG (hIgG)-C. neoformans complexes exhibited more binding to CHO-K1 cells expressing FCGR3A 158V than to those expressing FCGR3A 158F. In cytotoxicity assays, natural killer (NK) cells expressing FCGR3A 158V induced more C. neoformans-infected monocyte cytotoxicity than those expressing FCGR3A 158F.

"We found that this high affinity Fc receptor polymorphism was very highly overrepresented in the patients that got cryptococcal disease," said senior author Dr. Liise-anne Pirofski, professor of microbiology and immunology at the Albert Einstein College of Medicine. "Patients with two copies of the high affinity Fc receptor gene had an almost 20-fold increased risk of contracting the disease. It is surprising that a receptor involved with a higher capacity to bind immune complexes would be associated with susceptibility in patients with HIV, since phagocytosis of immune complexes is thought of as a mechanism for fighting invading microorganisms."

"This could be the beginning of a predictive test, at least in high-risk people," said Dr. Pirofski. "I think that we are ready to study this receptor further as a risk factor for disease in larger cohorts."

The study was published in the August 27, 2013, online edition of the journal mBio.

Related Links:

Albert Einstein College of Medicine



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.